Προσφορά για την Προμήθεια Erlotinib ή Gefitinib για την Αντιμετώπιση Περιστατικών με μη Μικροκυτταρικό Καρκίνο των Πνευμόνων και Μετάλλαξη του EGFR (Αγωγή 1ης Γραμμής) 115/2013

Cyprus · Medical equipment & pharmaceuticals

different companies won awards here

333

of the awards went to the three most frequent winners

19%

winners of the last 12 months were new here

104 of 225

buyers awarded contracts here

30

Based on 3,894 awards with a named winner over the last 3 years. Counted by award, not by value, because lot and framework amounts are not comparable. Concentrated means the three most frequent winners took 65% or more of the awards; many suppliers, under 35% with at least ten different winners. New: no award from the same buyer or market in the two years before.

Competition

tenders per lot on average (open and restricted procedures)

2.6

of those lots received a single tender

38%

of the awards went to companies based in another country

5%

As the official award notices state them, over the last 3 years. Tenders per lot count open and restricted procedures only: in a negotiated procedure or a direct award a single tender is the procedure itself. The country is the one the notice gives for the winner.